Development of Lyophilised Eudragit® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration

Author:

Lombardo Rosamaria1ORCID,Ruponen Marika2,Rautio Jarkko2ORCID,Ghelardini Carla3,Di Cesare Mannelli Lorenzo3ORCID,Calosi Laura4,Bani Daniele4ORCID,Lampinen Riikka5ORCID,Kanninen Katja M.5ORCID,Koivisto Anne M.678,Penttilä Elina9,Löppönen Heikki9,Pignatello Rosario110ORCID

Affiliation:

1. Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy

2. School of Pharmacy, University of Eastern Finland, Yliopistonranta 1C, 70210 Kuopio, Finland

3. Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)—Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy

4. Platform of Imaging, Department of Experimental & Clinical Medicine, University of Florence, 50139 Florence, Italy

5. A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland

6. Brain Research Unit, Department of Neurology, School of Medicine, University of Eastern Finland, 70200 Kuopio, Finland

7. Department of Neurology, Neuro Centre, Kuopio University Hospital, 70210 Kuopio, Finland

8. Department of Neurology and Geriatrics, Helsinki University Hospital and Neurosciences, Faculty of Medcine, University of Helsinki, 00290 Helsinki, Finland

9. Department of Otorhinolaryngology, University of Eastern Finland, Kuopio University Hospital, 70210 Kuopio, Finland

10. NANOMED—Research Centre on Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy

Abstract

Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large first-pass effect, while the i.m. route is often painful, with low patient compliance and requiring specialised personnel. Moreover, CZP has a very low aqueous solubility. This study proposes the intranasal route as an alternative route of administration for CZP, through its encapsulation in polymeric nanoparticles (NPs) based on Eudragit® RS100 and RL100 copolymers. Slow-release polymeric NPs with dimensions around 400–500 nm were formulated to reside and release CZP in the nasal cavity, where it can be absorbed through the nasal mucosa and reach the systemic circulation. CZP-EUD-NPs showed a controlled release of CZP for up to 8 h. Furthermore, to reduce mucociliary clearance and increase the residence time of NPs in the nasal cavity to improve drug bioavailability, mucoadhesive NPs were formulated. This study shows that the NPs already exhibited strong electrostatic interactions with mucin at time zero due to the presence of the positive charge of the used copolymers. Furthermore, to improve the solubility, diffusion and adsorption of CZPs and the storage stability of the formulation, it was lyophilised using 5% (w/v) HP-β-CD as a cryoprotectant. It ensured the preservation of the NPs’ size, PDI and charge upon reconstitution. Moreover, physicochemical characterisation studies of solid-state NPs were performed. Finally, toxicity studies were performed in vitro on MDCKII cells and primary human olfactory mucosa cells and in vivo on the nasal mucosa of CD-1 mice. The latter showed non-toxicity of B-EUD-NPs and mild CZP-EUD-NP-induced tissue abnormalities.

Funder

PhD program in Neurosciences, XXXVI cycle, University of Catania

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference48 articles.

1. Institute of Health Metrics and Evaluation (IHME) (2023, April 05). Global Health Data Exchange (GHDx). Available online: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7.

2. Pires, P.C., Paiva-Santos, A.C., and Veiga, F. (2022). Antipsychotics-Loaded Nanometric Emulsions for Brain Delivery. Pharmaceutics, 14.

3. Clozapine versus typical neuroleptic medication for schizophrenia;Wahlbeck;Cochrane Database Syst. Rev.,2000

4. Development and evaluation of clozapine intranasal mucoadhesive in situ gels for brain targeting;Ravikrishna;J. Drug Deliv. Ther.,2019

5. Alternative Routes of Administration of Clozapine;Gee;CNS Drugs,2022

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3